Recombinant Human C-C Chemokine Receptor Type 2 (CCR2) Protein (His/Tag-Free), Active

Name: Recombinant Human C-C Chemokine Receptor Type 2 (CCR2) Protein (His/Tag-Free), Active
Brand: Beta LifeScience
SKU: BLC-06115P
Availability: InStock

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human C-C Chemokine Receptor Type 2 (CCR2) Protein (His/Tag-Free), Active is produced by our expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Activity	Measured by its binding ability in a functional ELISA. Immobilized CCR2 at 1 μg/ml can bind human CCL2, the EC50 of human CCL2 protein is 41.51-83.15 μg/ml.
Uniprotkb	P41597
Target Symbol	CCR2
Synonyms	CCR2; CMKBR2; C-C chemokine receptor type 2; C-C CKR-2; CC-CKR-2; CCR-2; CCR2; Monocyte chemoattractant protein 1 receptor; MCP-1-R; CD antigen CD192
Species	Homo sapiens (Human)
Tag	N-His/Tag-Free
Target Protein Sequence	MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYSLVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAHSAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALKARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNNFHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVIFTIMIVYFLFWTPYNIVILLNTFQEFFGLSNCESTSQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSLFHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGLLDGRGKGKSIGRAPEASLQDKEGA
Expression Range	1-374aa
Protein Length	Full Length
Mol. Weight	45.4 kDa
Research Area	Cancer
Form	Lyophilized powder
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Key functional receptor for CCL2 but can also bind CCL7 and CCL12. Its binding with CCL2 on monocytes and macrophages mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion (Probable). Also acts as a receptor for the beta-defensin DEFB106A/DEFB106B. Regulates the expression of T-cell inflammatory cytokines and T-cell differentiation, promoting the differentiation of T-cells into T-helper 17 cells (Th17) during inflammation. Facilitates the export of mature thymocytes by enhancing directional movement of thymocytes to sphingosine-1-phosphate stimulation and up-regulation of S1P1R expression; signals through the JAK-STAT pathway to regulate FOXO1 activity leading to an increased expression of S1P1R. Plays an important role in mediating peripheral nerve injury-induced neuropathic pain. Increases NMDA-mediated synaptic transmission in both dopamine D1 and D2 receptor-containing neurons, which may be caused by MAPK/ERK-dependent phosphorylation of GRIN2B/NMDAR2B. Mediates the recruitment of macrophages and monocytes to the injury site following brain injury.; (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection.
Subcellular Location	Cell membrane; Multi-pass membrane protein.
Protein Families	G-protein coupled receptor 1 family
Database References	HGNC: 1603 OMIM: 601267 KEGG: hsa:729230 STRING: 9606.ENSP00000292301 UniGene: PMID: 30138893 this study shows that CCR2 is upregulated on peripheral T cells in osteoarthritis PMID: 30403025 The A allele of CCR2 rs1799864 was associated with a higher MCP-1 level in AD and MCI patients. PMID: 29352259 Study results revealed that CCR2 promotes epithelialtomesenchymal transition through MMP2 in liver cancer. PMID: 30132565 NOX4 is induced in early alcoholic liver injury and regulates CCR2/CCL2 mRNA stability thereby promoting recruitment of inflammatory cells and production of proinflammatory cytokines. PMID: 28383062 T cell-stimulated CLL cells actively recruited monocytes; recruitment critically depended on the C-C-motif-chemokine-receptor-2 axis. PMID: 28971904 Study found that the activation of CCR2 by its ligand CCL2 increased the expression of SMO and Gli-1, resulting in Hh pathway activation, epithelial-mesenchymal transition and hepatocellular carcinoma cell invasion. PMID: 29115520 results confirmed that the CCR2 3'UTR acts as a metastasis suppressor by acting as a ceRNA for STARD13 and thus inhibiting RhoA-ROCK1-MLC-F-actin pathway in breast cancer cells. PMID: 28818997 It can be concluded that MCP-1 and CCR2 polymorphisms are not associated with AgP in Turkish population. PMID: 28458180 beta-arrestin2/AP-1-dependent beta2AR signaling has a critical role in the regulation of CCR2 expression and recruitment of leukocytes to the heart following injury PMID: 27956622 Results indicated that MCP-1 and CCR2 polymorphisms may influence the progression of IgAN, but not increase/decrease its susceptibility PMID: 27788494 High CCR2 expression is associated gastric cancer. PMID: 26992207 Our data strongly support the use of CCR2 and CD180 mRNAs as whole blood pharmacodynamic (PD)biomarkers for BRD4 inhibitors, especially in situations where paired tumor biopsies are unavailable. In addition, they can be used as tumor-based PD biomarkers for hematologic tumors. PMID: 28073847 Through experiments with chimeras of MCP-1 and MCP-3, we identified the chemokine amino-terminal region as being the primary determinant of both the binding and signaling selectivity of these two chemokines at CCR2. PMID: 28536301 Comprehensive Computational Analysis of GWAS Loci Identifies CCR2 as a Candidate Gene for Celiac Disease Pathogenesis PMID: 28059456 Studies indicate manipulating CCL2-CCR2 interaction as a potential approach for combating metastatic disease. PMID: 26885690 Interruption of either CCL2-CCR2 signaling or cathepsin B function significantly impaired perineural invasion (PNI). PMID: 28951461 No statistically significant correlation was found between CRC and the 190 G/A CCR2 polymorphism with colorectal cancer prevalence PMID: 29154245 rs1799864 polymorphism significantly associated with occurrence risk of psoriasis vulgaris in Chinese population PMID: 29145242 CCR2 genetic variants were not associated with risk of atherosclerotic coronary heart disease and glucometabolic traits. PMID: 27013693 These data suggest that CCR1/CCR2B could be involved in clearing EBV-infected latency III B cells in immunocompetent individuals via directing the migration of these cells and attracting the chemokines-expressing immune cells. PMID: 28892735 systemic mRNA expression of CCR2 strongly differentiated children who failed to achieve asthma control with triamcinolone administration PMID: 27665382 Basophil migration into skin lesions of Systemic Lupus Erythematosus patients were observed, but not in normal skin tissue. This migration was related to the upregulation of chemokine receptors CCR1 and CCR2 on basophils. PMID: 28954264 The CCR2 (+190 G/A) GG genotype frequencies for patients were significantly higher in the stage III-IV cancer group ( p = 0.036), and A allele carriers were significantly higher in the stage I-II ovarian cancer group. PMID: 28650671 tumor-promoting role for CCL2 acting through CCR2 on the tumor microenvironment PMID: 27820834 The findings of the work indicate a role for Galphaq and/or Galpha14 and in CCR2a/CCR2b-stimulated Rho A GTPase-mediated serum response factor activation. PMID: 26823487 Endogenous TRAIL/TRAIL-R-mediated CCL2 secretion promotes accumulation of tumor-supportive immune cells in the cancer microenvironment. PMID: 28212753 CCL2/CCR2 axis is expressed in the majority of monocytoid Acute myeloid leukemia blasts PMID: 28045930 CCR2B and beta2AR signals to FLNa to stimulate its endocytosis and recycling to the plasma membrane. PMID: 27909248 this study shows that CYTL1 possesses chemotactic activity and demonstrates that its functional receptor is CCR2B PMID: 27084102 PCSK9 regulates monocyte CCR2 expression and chemotaxis. PMID: 28232185 CCR2-targeted therapy with PF-04136309 in combination with FOLFIRINOX is safe and tolerable PMID: 27055731 Binding of J113863 to CCR2 or CCR5 also induced the recruitment of beta-arrestin 2, whereas UCB35625 did not. UCB35625 induced the chemotaxis of L1.2 cells expressing CCR2 or CCR5. In contrast, J113863 induced the migration of L1.2-CCR2 cells but antagonized the chemokine-induced migration of L1.2-CCR5 cells. PMID: 27895119 CCL2 suppressed HDL internalization and cholesterol efflux via CCR2 induction and p42/44 MAPK activation in ECs. CCL2 induction may contribute to impair HDL function and form atherosclerosis in coronary artery disease. PMID: 27458015 High levels of TRAIL-R3 and CCR-2 expression in tumor epithelial cells identified patients with early breast cancer with poor outcomes. PMID: 28420351 X ray crystal structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists PMID: 27926736 Ingestion of an amino acid supplement immediately post-exercise appears to help maintain plasma MCP-1 concentrations and augment CCR2 expression in resistance trained men. PMID: 27384580 HUMSCs expressing ISZ-sTRAIL might be an efficient therapeutic approach against lung cancer and MCP-1/CCR2 axis is essential for the tumor tropism of HUMSCs PMID: 26733169 The authors demonstrate a positive correlation between CCR2 receptor gene polymorphism and a subgroup of breast cancer showing poor prognosis, which deserves further investigation in larger samples for validation. PMID: 25716470 Results of this study indicated that the CCL2-CCR2 axis was involved in the pathogenesis of oral lichen planus and was positively correlated with disease activity. PMID: 25893607 sCCL2 production possibly will be associated with the adiposity and polymorphic phenotypes of CCL2 and CCR2, in Mexican-Mestizos with insulin resistance PMID: 26839895 Increased CCR2 expression is associated with bladder cancer metastasis. PMID: 26556868 These findings suggested that the CCL2/CCR2 chemokine signaling may regulate the epithelial-mesenchymal transition. PMID: 26648448 CCR2 gene polymorphism (64I allele carriage) is a predisposing factor for allergy. PMID: 27534043 data suggest that the CCR2-64I polymorphism is associated with the protective effect to development of cervical lesions as well as in the protection to HPV 16 infection. PMID: 26982176 Ovarian cancer cells express both Hp and its receptor CCR2 but only after exposure to ascitic fluid, inducing moderated cell migration; results suggest that Hp-induced changes in the cell morphology, actin cytoskeleton structure, and migration ability of tumor cells, is possibly "preparing" these cells for the potential induction of the metastatic phenotype. PMID: 26211665 The frequencies of the rare alleles of CCR2, ITGB3, and 3'UTR of c-fms in the Old Believers are lower than in the sample of Novosibirsk Russians, and the rare allele of DBH is more frequent PMID: 27239844 Among HIV-seropositive samples 3.4% were homozygous CCR2-64I mutants, 17.8%) were heterozygous,78.8% were CCR2 wild type. PMID: 26300579 results suggest that senescent dermal fibroblasts recruit stem cells by secreting various factors and that the CCL2/CCR2 axis is one of the mechanisms underlying this phenomenon PMID: 25808810 Association of hydrogen sulfide with alterations of monocyte chemokine receptors, CCR2 and CX3CR1 in patients with coronary artery disease PMID: 26123579

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.